Gritstone bio, Inc. Profile Avatar - Palmy Investing

Gritstone bio, Inc.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid t…

Biotechnology
US, EmeryVille [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Gritstone bio, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of GRTS's Analysis
CIK: 1656634 CUSIP: 39868T105 ISIN: US39868T1051 LEI: - UEI: -
Secondary Listings
GRTS has no secondary listings inside our databases.